Amplia announced today that the Safety Review Committee has approved dose escalation and recruitment of a third patient cohort into the ACCENT clinical trial of AMP945 in pancreatic cancer patients.
This first stage of the trial is focused on finding the most effective dose of AMP945 to combine with gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer, and will continue until either a dose-limited signal is identified, or the pharmacodynamic effect of AMP945 reaches a plateau.
Amplia’s CEO and Managing Director Dr Chris Burns commented:
“We are very pleased that the data collected from the trial to date supports further dose escalation to a third cohort of patients. The data is tracking as predicted from our previous Phase 1 healthy volunteer study and with preclinical models, and we believe we are closing in on a dose to take forward into stage 2 of the ACCENT trial”
Click here to read today's ASX release